AGP Executive Report
Last update: 6 hours agoGeorgia Medical Cannabis Rollout: Fine Fettle opened its Evans dispensary June 26, just as Georgia’s expanded medical cannabis law took effect July 1—now allowing more conditions (including Lupus, HIV, and IBD) and enabling sales of flower, vaporizers, and inhalable products. CBD/Anxiety Research: Trait Biosciences highlighted CBD82S™ anxiety-reducing potential using a water-soluble CBD approach. CBD for Psychosis: A new study reports cannabidiol shows no significant benefit for treating psychotic disorders versus placebo/standard care, positioning CBD as experimental for these conditions. THC Product Ban Fight: Louisiana hemp sellers are racing against a federal clock (Sept. 30) as Congress nears a ban on consumable THC items like seltzers and edibles. Prison Contraband: Watchdog reports prisoners are smuggling and buying weight-loss and hair-loss meds (including Ozempic and Minoxidil), alongside cannabis, as gangs expand contraband supply. Obesity/Addition Drug Pipeline: MIRA Pharmaceuticals released preclinical formulation results for oral SKNY-1 with brain penetration and once-daily dosing potential.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
